4th Pediatric Infectious Diseases Conference
 
 
Home  Back   ISSN 0973 - 0958
 
User name :
Password :
FIND DIAGNOSIS
FIND DIAGNOSIS
Find Diagnosis
Pedi Poll
Today's Poll
Should teicoplannin, colistin be used in case of neonatal sepsis where culture does not reveal any organism_?
No, it should be used only after drug sensitivity report
Yes, under guidance of an infectious disease expert
PORPHYRIAS
PORPHYRIAS
Porphyrias : Treatment and Prevention of Acute Attacks
Porphyrias : Treatment and Prevention of Acute Attacks
Dr. Ira Shah
M.D, DCH(Gold Medalist), FCPS, DNB

Continued...

Q: How is an acute attack treated?

A. Treatment consists of both supportive and specific therapy.

Any patient in an acute attack requires

symptomatic treatment for the following conditions:


  • Pain : When mild, it can be controlled with aspirin, paracetamol or dihydrocodeine. For severe pain, pethidine or morphine may be required. Sleep diminishes pain, hence chlorpromazine with analgesics may be useful. Patients should be left undisturbed in a darkened room.

  • Nausea, vomiting and constipation : They can be controlled with chlorpromazine, prochlorperazine. If constipation is severe enough to cause obstipation, neostigmine may be useful.

  • Tachycardia & Hypertension : They are due to sympathetic overactivity and can be controlled by propranolol. If there is evidence of cardiovascular instability, continuous cardiac monitoring is required.

  • Convulsions Hyponatremia should be corrected by restricting fluid intake.

    It could also be a sign of hypertensive encephalopathy and blood pressure should be corrected. Convulsions are usually present only during an attack and remit as the symptoms resolve.


  • Peripheral neuropathy : Watch should be kept for respiratory fatigue. The expiratory peak flow rate should be monitored. If there is any decrease in this rate, the blood gases should be checked and patient should be in ICU with facilities for assisted ventilation. Proper physiotherapy should be maintained in a paralyzed patient.

Specific therapy consists of :

  1. Hematin therapy - Hematin is the end product of the heme pathway. Thus, it acts by supplementing the depleted heme pool and repressing the activity of the initial enzymes of heme biosynthesis, thus reducing the overproduction of porphyrins. In the acute attack it is given intravenously. There are no major side effects except for phlebitis around the injection site. This can be prevented by giving hematin with human albumin solution to which it will bind. It may also cause prolongation of prothrombin and partial thromboplastin times, which revert back to normal on stopping the drug. In patients with renal failure, the dose of drugs should be reduced.

  2. High Carbohydrate intake - Most patients have nausea and vomiting in the attack and their poor carbohydrate intake further aggravates the disease. Hence, glucose should be supplemented either orally or intravenously.
Q: How do you prevent an acute attack?

A. By maintaining a regular diet, avoiding alcohol and certain drugs, most of the attacks can be prevented. For patients who have attacks premenstrually, prophylactic LHRH analogues can be tried long term. Patients who have acute attacks, should avoid pregnancy till they are free of symptomatic attacks for at least 18 months as pregnancy may precipitation an acute attack.

To avoid the photosensitivity seen in VP and HCP, Beta-Carotene treatment may be useful.

Q: How do you test for porphyria in family member?

A. Since acute porphyrias are autosomal dominant conditions, there is 50 % chance that the child may be affected if one of the parent has the disease. However, the disease may remain latent for a prolonged time. Latent cases can be diagnosed by measuring porphyrins and their precursors in urine, faces and blood, or measuring the various enzymes of the heme biosynthetic pathway. Young children may not show signs of their porphyria till puberty and laboratory tests may not even pick it up till then. Hence, it is safer to have to children follow the same precautions to minimize the risk. These children should be tested every two years from the age of 12 till they are 20 years old. If the tests are still negative, it is unlikely that the child may suffer from porphyria. However, the child may still have the defective gene, hence it is wise that no member of a porphyric family should take such drugs until essential.

Q: What is the skin problem in porphyria?

A. Skin problems in porphyria are usually acquired conditions. Patients with VP, HC, CP and PCT have a very sensitive skin, which is easily damaged. Sunlight often causes the skin to become fragile particularly in those areas exposed to light like hands, faces, neck, legs and feet. Their skin develops blisters and sores. Long term, their skin become thin, dark, scarred and often hairy. EPP and CP present at much younger age and have severe symptoms.

Q: How do you prevent these skin problems?

A. The best way to treat the skin condition is to prevent it. Avoiding sunlight is the most beneficial therapy. Sun-exposed areas can be protected by wearing long sleeves, gloves and a hat. Patient should go out only in early morning or late afternoon. Sunscreens, which can help, are opaque zinc or titanium oxide, however, they are thick and greasy.

Q: What is the treatment?

A. There is no cure for porphyria. However, it can be made less severe. Patients with PCT should avoid alcohol. If skin conditions remain bad, venesection is indicated. This removes about 10cc\kg\body weight of patient's blood at regular intervals usually fortnightly for about eight weeks. Patients with EPP should be regularly tested for liver dysfunction.

Last created on 23-02-2001
Last updated on 30-04-2007



 
 
Educational Section
 
Disclaimer:
The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
 
copyright ©2011 website design & development by Levioza
Follow Us
Follow us on :
Folllow Us